BioCentury
ARTICLE | Clinical News

Heptares' selective M1 agonist bound for Phase II

February 11, 2016 1:14 AM UTC

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565) reported data from a Phase Ib study of muscarinic acetylcholine receptor M1 (CHRM1; HM1) agonist HTL9936, its most advanced internal candidate. Heptares said it plans to start Phase II testing of at least one M1 agonist in late 2016 to treat dementia and schizophrenia. The company has another M1 agonist, HTL18318, in Phase I.

Heptares said HTL9936 led to significant changes in brain activity associated with cognition as measured by electroencephalography (EEG) biomarkers, even at low doses and blood concentrations, and with no gastrointestinal side effects. The study enrolled 28 healthy elderly subjects, and tested different doses of HTL9936 on measures of brain activity. ...